About Roivant Sciences
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.
The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs.
In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
|
|
|
51-200 employees
View all Roivant Sciences employees
|
|
Biotechnology Research
|
|
(919) 767-3277
|
|
151 W 42nd St, 15th Floor, New York, New York 10036, US
|
|
2014
|
Roivant Sciences Alternatives
Frequently Asked Questions about Roivant Sciences
Regina Sav is the CEO of Roivant Sciences. To contact Regina Sav email at [email protected].
The decision makers in Roivant Sciences are Cheryl Blasie, Cory Mackin, Drew Fromkin, etc. Click to Find Roivant Sciences decision makers emails.
Roivant Sciences Staff Directory
Search Roivant Sciences Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
